• Advancing Saudi Arabia’s Position as a Global Healthcare Innovation Leader Aligned with Vision 2030

Riyadh, Saudi Arabia – 18 February 2026: Novartis commenced 2026 with two significant recognitions in Saudi Arabia, affirming its leadership in clinical research and contributions to the Kingdom’s developing healthcare sector.

At the Clinical Trials Transformation Conference: Unraveling the Future in Riyadh, Novartis was awarded First Place in the Clinical Research Contribution Award, presented by King Faisal Specialist Hospital & Research Centre. This accolade acknowledges Novartis’ commitment to advancing high-quality clinical research in Saudi Arabia and enhancing local scientific expertise.

Continue reading Novartis Receives Dual Recognition for Clinical Research Excellence in Saudi Arabia →

A call for early testing and broader public awareness

Media webinar titled “Introducing the Little (a) with Big Consequences” warned that one in five people unknowingly carry a genetic risk for heart disease, stressing the urgent need for greater awareness and screening.

Dubai, United Arab Emirates, 24 September 2025 — Novartis today convened leading experts from science, policy, patient advocacy, and clinical care to spotlight elevated lipoprotein(a), or Lp(a) – a little-known but highly prevalent genetic risk factor for cardiovascular disease (CVD) that affect 1 in 5 people worldwide.¹ 

The global educational webinar, titled “Introducing the Little (a) with Big Consequences”, was attended by journalists from leading media publications across the UAE. Held ahead of World Heart Day (29 September 2025), the session was part of a global awareness campaign by Novartis in collaboration with Global Heart Hub to raise awareness of elevated lipoprotein(a) and advance equitable access to testing and care worldwide.

Continue reading Understanding lipoprotein(a) and its genetic impact on the heart →